Loading...

Abbott India

NSEI:ABBOTINDIA
Snowflake Description

Flawless balance sheet established dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ABBOTINDIA
NSEI
₹182B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Abbott India Limited operates as a pharmaceutical company in India. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
ABBOTINDIA Share Price and Events
7 Day Returns
-3.6%
NSEI:ABBOTINDIA
0.6%
IN Pharmaceuticals
-0.5%
IN Market
1 Year Returns
17.2%
NSEI:ABBOTINDIA
-9.7%
IN Pharmaceuticals
-2.4%
IN Market
ABBOTINDIA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Abbott India (ABBOTINDIA) -3.6% 1.3% 9.6% 17.2% 81.8% 310.6%
IN Pharmaceuticals 0.6% 2.2% -12.1% -9.7% -24.5% 5.2%
IN Market -0.5% -2% -4.8% -2.4% 21.3% 31.2%
1 Year Return vs Industry and Market
  • ABBOTINDIA outperformed the Pharmaceuticals industry which returned -9.7% over the past year.
  • ABBOTINDIA outperformed the Market in India which returned -2.4% over the past year.
Price Volatility
ABBOTINDIA
Industry
5yr Volatility vs Market

Value

 Is Abbott India undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Abbott India to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Abbott India.

NSEI:ABBOTINDIA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14.6%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:ABBOTINDIA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.732 (1 + (1- 35%) (0%))
0.82
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.82 * 8.6%)
14.6%

Discounted Cash Flow Calculation for NSEI:ABBOTINDIA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Abbott India is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NSEI:ABBOTINDIA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 14.6%)
2020 3,860.00 Analyst x1 3,368.11
2021 6,198.00 Analyst x2 4,718.99
2022 8,051.57 Est @ 29.91% 5,349.06
2023 9,919.46 Est @ 23.2% 5,750.21
2024 11,754.99 Est @ 18.5% 5,945.89
2025 13,543.88 Est @ 15.22% 5,977.73
2026 15,293.42 Est @ 12.92% 5,889.75
2027 17,022.71 Est @ 11.31% 5,720.31
2028 18,755.64 Est @ 10.18% 5,499.49
2029 20,517.00 Est @ 9.39% 5,249.32
Present value of next 10 years cash flows ₹53,468.86
NSEI:ABBOTINDIA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₹20,517.00 × (1 + 7.55%) ÷ (14.6% – 7.55%)
₹312,800.48
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹312,800.48 ÷ (1 + 14.6%)10
₹80,030.66
NSEI:ABBOTINDIA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹53,468.86 + ₹80,030.66
₹133,499.52
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹133,499.52 / 21.25
₹6282.54
NSEI:ABBOTINDIA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:ABBOTINDIA represents 1.00304x of BSE:500488
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00304x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 6,282.54 x 1.00304
₹6,301.63
Value per share (INR) From above. ₹6,301.63
Current discount Discount to share price of ₹8,572.80
= -1 x (₹8,572.80 - ₹6,301.63) / ₹6,301.63
-36%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Abbott India is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Abbott India's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Abbott India's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:ABBOTINDIA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹211.93
BSE:500488 Share Price ** BSE (2019-07-19) in INR ₹8546.85
India Pharmaceuticals Industry PE Ratio Median Figure of 116 Publicly-Listed Pharmaceuticals Companies 16.68x
India Market PE Ratio Median Figure of 2,834 Publicly-Listed Companies 14.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Abbott India.

NSEI:ABBOTINDIA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:500488 Share Price ÷ EPS (both in INR)

= 8546.85 ÷ 211.93

40.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abbott India is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
  • Abbott India is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Abbott India's expected growth come at a high price?
Raw Data
NSEI:ABBOTINDIA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 40.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
16.5%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 31 Publicly-Listed Pharmaceuticals Companies 1.48x
India Market PEG Ratio Median Figure of 535 Publicly-Listed Companies 1.29x

*Line of best fit is calculated by linear regression .

NSEI:ABBOTINDIA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 40.33x ÷ 16.5%

2.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abbott India is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Abbott India's assets?
Raw Data
NSEI:ABBOTINDIA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹945.47
BSE:500488 Share Price * BSE (2019-07-19) in INR ₹8546.85
India Pharmaceuticals Industry PB Ratio Median Figure of 135 Publicly-Listed Pharmaceuticals Companies 1.53x
India Market PB Ratio Median Figure of 3,669 Publicly-Listed Companies 0.94x
NSEI:ABBOTINDIA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:500488 Share Price ÷ Book Value per Share (both in INR)

= 8546.85 ÷ 945.47

9.04x

* Primary Listing of Abbott India.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abbott India is overvalued based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Abbott India's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Abbott India has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Abbott India expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Abbott India expected to grow at an attractive rate?
  • Abbott India's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Abbott India's earnings growth is positive but not above the India market average.
  • Abbott India's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
NSEI:ABBOTINDIA Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:ABBOTINDIA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 16.5%
NSEI:ABBOTINDIA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 11.9%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.1%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 11.1%
India Market Earnings Growth Rate Market Cap Weighted Average 17%
India Market Revenue Growth Rate Market Cap Weighted Average 9.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:ABBOTINDIA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:ABBOTINDIA Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 46,620 4,591 6,238 4
2020-03-31 41,278 3,122 5,251 4
NSEI:ABBOTINDIA Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 36,786 4,503
2018-12-31 35,606 4,372
2018-09-30 34,941 4,355
2018-06-30 34,460 4,354
2018-03-31 32,985 1,527 4,012
2017-12-31 32,242 3,432
2017-09-30 30,893 3,134
2017-06-30 28,794 2,509
2017-03-31 29,026 3,072 2,766
2016-12-31 28,959 2,980
2016-09-30 28,097 2,802
2016-06-30 27,293 2,663

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Abbott India's earnings are expected to grow by 16.5% yearly, however this is not considered high growth (20% yearly).
  • Abbott India's revenue is expected to grow by 11.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:ABBOTINDIA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Abbott India Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:ABBOTINDIA Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 295.17 323.50 274.08 4.00
2020-03-31 247.12 254.40 243.30 4.00
NSEI:ABBOTINDIA Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 211.93
2018-12-31 205.75
2018-09-30 204.97
2018-06-30 204.88
2018-03-31 188.81
2017-12-31 161.51
2017-09-30 147.48
2017-06-30 118.07
2017-03-31 130.19
2016-12-31 140.63
2016-09-30 132.12
2016-06-30 125.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Abbott India is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Abbott India's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Abbott India has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Abbott India performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Abbott India's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Abbott India's year on year earnings growth rate has been positive over the past 5 years.
  • Abbott India's 1-year earnings growth is less than its 5-year average (12.2% vs 18.1%)
  • Abbott India's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (12.2% vs 24.7%).
Earnings and Revenue History
Abbott India's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Abbott India Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:ABBOTINDIA Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 36,786.00 4,503.30 4,355.80
2018-12-31 35,605.69 4,371.98 5,726.96
2018-09-30 34,941.25 4,355.28 5,574.96
2018-06-30 34,460.18 4,353.68 5,506.06
2018-03-31 32,985.04 4,012.18 5,324.96
2017-12-31 32,242.38 3,432.19 4,760.10
2017-09-30 30,892.88 3,133.89 4,727.30
2017-06-30 28,794.18 2,508.89 4,613.00
2017-03-31 29,025.58 2,766.49 4,516.59
2016-12-31 28,959.11 2,979.58 4,401.56
2016-09-30 28,097.31 2,801.88 4,402.86
2016-06-30 27,292.81 2,663.28 4,402.76
2016-03-31 26,145.04 2,552.50 4,444.25
2015-12-31 25,379.66 2,503.79 6,194.04
2015-09-30 24,504.06 2,445.49 6,108.74
2015-06-30 23,950.16 2,465.89 6,015.54
2015-03-31 22,893.26 2,289.59 4,001.86
2014-12-31 22,007.62 2,175.91 5,943.14
2014-09-30 21,102.92 2,065.21 5,706.24
2014-06-30 19,776.02 1,879.71 5,557.94
2014-03-31 18,693.84 1,667.51 5,541.02
2013-12-31 17,527.40 1,600.60 2,312.50
2013-09-30 17,580.49 1,272.87 4,296.79
2013-06-30 17,196.19 1,495.07 4,249.39
2013-03-31 16,927.69 1,202.37 4,199.39
2012-12-31 16,526.89 1,156.17 4,120.12
2012-09-30 15,858.40 1,027.33 4,116.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Abbott India has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Abbott India used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • Abbott India's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Abbott India's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Abbott India has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Abbott India's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Abbott India's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Abbott India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Abbott India's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Abbott India's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Abbott India has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Abbott India Company Filings, last reported 3 months ago.

NSEI:ABBOTINDIA Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 20,085.90 0.00 16,842.90
2018-12-31 17,761.20 0.00 13,222.10
2018-09-30 17,761.20 0.00 13,222.10
2018-06-30 16,927.61 0.00 10,250.27
2018-03-31 16,927.61 0.00 10,250.27
2017-12-31 14,733.70 0.00 11,966.70
2017-09-30 14,733.70 0.00 11,966.70
2017-06-30 13,869.44 0.00 10,848.36
2017-03-31 13,869.44 0.00 10,848.36
2016-12-31 12,565.20 0.00 8,845.80
2016-09-30 12,565.20 0.00 8,845.80
2016-06-30 11,076.42 0.00 8,394.22
2016-03-31 11,955.99 0.00 8,357.91
2015-12-31 10,677.90 0.00 7,159.30
2015-09-30 10,677.90 0.00 7,159.30
2015-06-30 9,375.28 0.00 6,438.94
2015-03-31 9,375.28 0.00 6,438.94
2014-12-31 9,025.30 0.00 5,589.70
2014-09-30 9,025.30 0.00 5,589.70
2014-06-30 7,878.51 0.00 4,628.42
2014-03-31 7,878.51 0.00 4,628.42
2013-12-31 8,066.40 0.00 3,680.70
2013-09-30 7,079.90 0.00 3,854.10
2013-06-30 7,079.90 0.00 3,854.10
2013-03-31 6,468.59 0.00 3,245.15
2012-12-31 6,468.59 0.00 3,233.43
2012-09-30 6,007.60 0.00 2,605.70
  • Abbott India has no debt.
  • Abbott India has not taken on any debt in the past 5 years.
  • Abbott India has no debt, it does not need to be covered by operating cash flow.
  • Abbott India has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Abbott India's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Abbott India has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Abbott India's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.76%
Current annual income from Abbott India dividends. Estimated to be 0.78% next year.
If you bought ₹2,000 of Abbott India shares you are expected to receive ₹15 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Abbott India's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.56%).
  • Abbott India's dividend is below the markets top 25% of dividend payers in India (2.23%).
Upcoming dividend payment

Purchase Abbott India before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:ABBOTINDIA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 74 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1446 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.6%
India Top 25% Dividend Yield 75th Percentile 2.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:ABBOTINDIA Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2021-03-31 67.50 2.00
2020-03-31 65.00 2.00
NSEI:ABBOTINDIA Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-05-27 65.000 0.767
2018-05-14 50.000 0.670
2017-05-19 40.000 0.826
2016-05-25 35.000 0.761
2015-05-27 31.000 0.642
2014-07-07 23.000 0.712
2014-05-28 23.000 1.204
2013-04-08 17.000 1.123
2013-02-20 17.000 1.249
2012-05-14 17.000 1.145
2011-04-27 17.000 1.141
2010-02-01 17.000 1.520
2010-01-29 17.000 2.269
2009-01-29 14.000 2.683

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Abbott India's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (4.4x coverage).
X
Income/ dividend checks
We assess Abbott India's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Abbott India afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Abbott India has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Abbott India's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ambati Venu
COMPENSATION ₹58,589,000
AGE 50
TENURE AS CEO 2.8 years
CEO Bio

Mr. Ambati Venu has been Managing Director at Abbott India Limited since September 29, 2016. Mr. Venu served as Executive Vice President and General Manager of Sales Eastern Region of Glaxosmithkline Consumer Healthcare Ltd. He has been an Additional Director at Abbott India Limited since September 29, 2016. Mr. Venu holds B. E. in Mechahical and P.G.D.M.

CEO Compensation
  • Ambati's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Ambati's remuneration is about average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Abbott India management team in years:

4
Average Tenure
56
Average Age
  • The tenure for the Abbott India management team is about average.
Management Team

Ambati Venu

TITLE
MD & Executive Director
COMPENSATION
₹59M
AGE
50
TENURE
2.8 yrs

Rajiv Sonalker

TITLE
CFO, Group Finance Director & Whole-time Director
COMPENSATION
₹25M
AGE
60
TENURE
13.5 yrs

Krupa Anandpara

TITLE
Head of Secretarial
COMPENSATION
₹6M

Nitu Bhushan

TITLE
Director of Human Resources

Mike Warmuth

TITLE
Executive Vice President of Pharmaceuticals Division
AGE
56

T. Prasad

TITLE
Associate Director of Ex India
TENURE
4 yrs
Board of Directors Tenure

Average tenure and age of the Abbott India board of directors in years:

1.6
Average Tenure
60
Average Age
  • The average tenure for the Abbott India board of directors is less than 3 years, this suggests a new board.
Board of Directors

Munir Shaikh

TITLE
Chairman of the Board
COMPENSATION
₹1M
AGE
76

Ambati Venu

TITLE
MD & Executive Director
COMPENSATION
₹59M
AGE
50
TENURE
2.8 yrs

Rajiv Sonalker

TITLE
CFO, Group Finance Director & Whole-time Director
COMPENSATION
₹25M
AGE
60
TENURE
1.9 yrs

Kaiyomarz Marfatia

TITLE
Non-Executive Director
COMPENSATION
₹16M
AGE
63
TENURE
8.3 yrs

Sudarshan Jain

TITLE
Additional & Independent Director
COMPENSATION
₹6M
AGE
64
TENURE
0.3 yrs

Anisha Motwani

TITLE
Independent Director
AGE
56
TENURE
1.3 yrs

Krishna Sahni

TITLE
Independent Director
COMPENSATION
₹2M
AGE
72
TENURE
4.8 yrs

Jawed Zia

TITLE
Non-Executive Director
AGE
56
TENURE
1.1 yrs

Mark Murphy

TITLE
Additional Non-Executive Director
AGE
50
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Abbott India's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Abbott India has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should We Be Delighted With Abbott India Limited's (NSE:ABBOTINDIA) ROE Of 22%?

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Abbott India: 22% = ₹4.5b ÷ ₹20b (Based on the trailing twelve months to March 2019.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … Does Abbott India Have A Good Return On Equity? … Combining Abbott India's Debt And Its 22% Return On Equity One positive for shareholders is that Abbott India does not have any net debt!

Simply Wall St -

What Does Abbott India Limited's (NSE:ABBOTINDIA) P/E Ratio Tell You?

We'll look at Abbott India Limited's (NSE:ABBOTINDIA) P/E ratio and reflect on what it tells us about the company's share price. … See our latest analysis for Abbott India How Do I Calculate Abbott India's Price To Earnings Ratio? … The formula for P/E is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for Abbott India: P/E of 42.04 = ₹8908.55 ÷ ₹211.93 (Based on the trailing twelve months to March 2019.) Is A High Price-to-Earnings Ratio Good?

Simply Wall St -

Does Abbott India Limited's (NSE:ABBOTINDIA) CEO Salary Compare Well With Others?

See our latest analysis for Abbott India How Does Ambati Venu's Compensation Compare With Similar Sized Companies? … It would therefore appear that Abbott India Limited pays Ambati Venu more than the median CEO remuneration at companies of a similar size, in the same market. … We compared total CEO remuneration at Abbott India Limited with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Is Abbott India Limited (NSE:ABBOTINDIA) Worth ₹7,784 Based On Its Intrinsic Value?

Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) estimate 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF (₹, Millions) ₹3.64k ₹4.20k ₹6.96k ₹8.87k ₹10.76k ₹12.62k ₹14.43k ₹16.21k ₹17.97k ₹19.75k Growth Rate Estimate Source Analyst x1 Analyst x2 Analyst x1 Est @ 27.37% Est @ 21.42% Est @ 17.26% Est @ 14.35% Est @ 12.31% Est @ 10.88% Est @ 9.88% Present Value (₹, Millions) Discounted @ 14.43% ₹3.18k ₹3.21k ₹4.65k ₹5.17k ₹5.49k ₹5.62k ₹5.62k ₹5.51k ₹5.34k ₹5.13k Present Value of 10-year Cash Flow (PVCF)= ₹48.92b "Est" = FCF growth rate estimated by Simply Wall St We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = ₹20b × (1 + 7.6%) ÷ (14.4% – 7.6%) = ₹309b Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = ₹₹309b ÷ ( 1 + 14.4%)10 = ₹80.20b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is ₹129.12b. … NSEI:ABBOTINDIA Intrinsic value, May 23rd 2019 The assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

Can We See Significant Institutional Ownership On The Abbott India Limited (NSE:ABBOTINDIA) Share Register?

View our latest analysis for Abbott India NSEI:ABBOTINDIA Ownership Summary, May 10th 2019 What Does The Institutional Ownership Tell Us About Abbott India? … As you can see, institutional investors own 8.8% of Abbott India. … Public Company Ownership Public companies currently own 75% of ABBOTINDIA stock.

Simply Wall St -

Abbott India's (NSE:ABBOTINDIA) Wonderful 319% Share Price Increase Shows How Capitalism Can Build Wealth

To wit, the Abbott India Limited (NSE:ABBOTINDIA) share price has soared 319% over five years. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … Over half a decade, Abbott India managed to grow its earnings per share at 22% a year.

Simply Wall St -

Is Abbott India Limited (NSE:ABBOTINDIA) Potentially Underrated?

Attractive stocks have exceptional fundamentals. … In the case of Abbott India Limited (NSE:ABBOTINDIA), there's

Simply Wall St -

How To Take Advantage Of Abbott India Limited (NSE:ABBOTINDIA) In A Bear Market

I'm talking about the well-proven, robust track record Abbott India Limited. … Check out our latest analysis for Abbott India. … Abbott India Limited operates as a pharmaceutical company in India

Simply Wall St -

Should We Worry About Abbott India Limited's (NSE:ABBOTINDIA) P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … We'll look at Abbott India Limited's (NSE:ABBOTINDIA) P/E ratio and reflect on what it tells us about the company's share price. … Abbott India has a price to earnings ratio of 35.4, based on the last twelve months.

Simply Wall St -

Is Abbott India Limited (NSE:ABBOTINDIA) A High Quality Stock To Own?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Abbott India has a return on equity of 25% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Company Info

Description

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, CNS, metabolics, general care, vitamins, vaccines, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was incorporated in 1944 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Laboratories.

Details
Name: Abbott India Limited
ABBOTINDIA
Exchange: NSEI
Founded: 1944
₹181,614,596,798
21,249,302
Website: http://www.abbott.co.in
Address: Abbott India Limited
Godrej BKC,
16th Floor,
Mumbai,
Maharashtra, 400051,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 500488 Equity Shares Mumbai Stock Exchange IN INR 23. Sep 1999
NSEI ABBOTINDIA Equity Shares National Stock Exchange of India IN INR 23. Sep 1999
Number of employees
Current staff
Staff numbers
2,910
Abbott India employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 13:00
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/11
Last earnings filing: 2019/05/27
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.